In a preclinical model of BRAF(V600)-mutated metastatic melanoma, anti­PD1 therapy in combination with BRAF and MEK inhibitors contributed to complete tumor regression with increasing T-cell infiltration into tumors (144). Here, BRAF is linked to neoplasm.